Express Pharma

JANUARY 2, 2025

The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in 2023 to $9.9 per cent from $2.2

Diabetes 105

Diabetes Vaccines Compounding 105

pharmaphorum

DECEMBER 10, 2020

Eli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be vindicated, according to its first phase 3 trial readout. More than half (51.7%) of participants in the treatment arm achieved an A1C less than 5.7% – the level seen in people without diabetes.

Diabetes 64

Diabetes Vaccines 64

STAT

SEPTEMBER 12, 2024

billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate, STAT writes. So here are some items of interest. Have a great day, everyone. … Moderna plans to cut its annual spending on research and development by 23%, or $1.1

Packaging 145

Packaging Diabetes Vaccines 145